Immunovant, Inc. SEC filings IMVT
Immunovant, Inc. has 648 filings in SEC EDGAR's recent list, going back to Jan 23, 2019. Its latest annual report, Form ARS, was filed on Jul 22, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 3, 2026 (shareholder vote results). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Jan 21, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 28, 2024 | — |
| CORRESP | Letter to the SEC | Feb 13, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 17, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 18, 2021 | — |
| CORRESP | Letter to the SEC | Feb 17, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 2, 2021 | — |
| EFFECT | Filing | Jan 14, 2021 | — |
| CORRESP | Letter to the SEC | Jan 12, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 11, 2021 | — |
| POS EX | Filing | Sep 2, 2020 | — |
| EFFECT | Filing | Sep 1, 2020 | — |
| CORRESP | Letter to the SEC | Aug 31, 2020 | — |
| CORRESP | Letter to the SEC | Aug 31, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2020 | — |
| DRS | Filing | Aug 19, 2020 | — |
| 25-NSE | Delisting notice | Jun 15, 2020 | — |
| EFFECT | Filing | Apr 14, 2020 | — |
| POS EX | Filing | Apr 14, 2020 | — |
| CORRESP | Letter to the SEC | Apr 10, 2020 | — |
| CORRESP | Letter to the SEC | Apr 10, 2020 | — |
| EFFECT | Filing | Apr 9, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2020 | — |
| CORRESP | Letter to the SEC | Apr 8, 2020 | — |
| DRS | Filing | Apr 1, 2020 | — |
| CORRESP | Letter to the SEC | Feb 28, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 28, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 6, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2020 | — |
| DEFR14A | Revised definitive proxy statement | Nov 29, 2019 | — |
| PRER14A | Proxy statement | Nov 25, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2019 | — |
| PRER14A | Prelminary proxy statement | Nov 6, 2019 | — |
| CORRESP | Letter to the SEC | Nov 5, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 31, 2019 | — |
| EFFECT | Filing | May 9, 2019 | — |
| CERT | Filing | May 9, 2019 | — |
| CORRESP | Letter to the SEC | May 9, 2019 | — |
| 8-A12B | Filing | May 9, 2019 | — |
| CORRESP | Letter to the SEC | May 8, 2019 | — |
| CORRESP | Letter to the SEC | May 3, 2019 | — |
| UPLOAD | Letter from the SEC | May 1, 2019 | — |
| DRS/A | Filing | Feb 26, 2019 | — |
| DRSLTR | Filing | Feb 25, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| DRS | Filing | Jan 23, 2019 | — |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMVT (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1764013
- Former names
- Health Sciences Acquisitions Corp (until Dec 20, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.